Novitzky N, Thomas V, Stubbings H, Hale G, Waldmann H
The University of Cape Town Leukaemia Centre and the Division of Haematology, Cape Town, South Africa.
Cytotherapy. 2004;6(5):450-6. doi: 10.1080/14653240410004970.
We studied the outcome of individuals with aplastic anemia conditioned with a radiation-containing regimen followed by an infusion of stem cell grafts that had been depleted of lymphocytes with CAMPATH-1H (antiCD52; humanised).
The conditioning regime consisted of fractionated (f) TBI 8 Gy followed by f total nodal irradiation (TNI) 6 Gy. In addition, patients received CY 60 mg/kg on 2 consecutive days. Cytokine-mobilized peripheral blood grafts from HLA-identical siblings were T-cell depleted with CAMPATH-1H 'in the bag'. CsA was commenced on day -1 and continued until day +90.
Seventeen heavily transfused patients with aplastic anemia, median age 18 years (range 14-56 years), were studied. The median time from diagnosis to transplantation was 172 days (range 34-443 days). The median CD34(+) cell number infused was 3.47 x 10(6)/kg (range 1.03-18.4 x 10(6)/kg). All patients engrafted. Recovery was fast and patients reached 0.5 x 10(9)/L polymorphs by median day 11 (range 9-17 days). Toxicity from the conditioning included grade 4 hematologic toxicity in all patients. Another major toxicity was gastrointestinal mucosal damage, which exceeded grade 2 in two instances. One patient developed thrombotic thrombocytopenic purpura, which responded to substitution of CsA with tacrolimus and plasmapheresis. Another patient, who had normal blood counts, died of infection on day 241. Chimerism studies at 6 months post-transplantation confirmed the donor origin of hematopoiesis in all seven patients tested. None of the patients developed acute or chronic GvHD. There was no delayed graft failure and 94% of patients had survived disease free at a median of 1303.5 days (range 216-2615 days) from graft infusion.
In this cohort of multiply transfused patients, the radiation-containing schedules described in this study led to universal engraftment with limited toxicity despite T-cell depletion. No patient developed GvHD or late graft failure. Lower doses of radiation-containing conditioning should be explored further.
我们研究了再生障碍性贫血患者在接受含放疗方案预处理后输注经CAMPATH-1H(抗CD52;人源化)去除淋巴细胞的干细胞移植物的结果。
预处理方案包括分次(f)全身照射(TBI)8 Gy,随后分次全淋巴结照射(TNI)6 Gy。此外,患者连续2天接受环磷酰胺(CY)60 mg/kg。来自 HLA 相同同胞的细胞因子动员外周血移植物在“袋内”用CAMPATH-1H去除T细胞。环孢素A(CsA)于移植前1天开始使用,并持续至移植后90天。
研究了17例重度输血的再生障碍性贫血患者,中位年龄18岁(范围14 - 56岁)。从诊断到移植的中位时间为172天(范围34 - 443天)。输注的中位CD34(+)细胞数为3.47×10⁶/kg(范围1.03 - 18.4×10⁶/kg)。所有患者均实现造血重建。恢复迅速,患者在移植后中位第11天(范围9 - 17天)中性粒细胞计数达到0.5×10⁹/L。预处理的毒性包括所有患者均出现4级血液学毒性。另一个主要毒性是胃肠道黏膜损伤,有2例超过2级。1例患者发生血栓性血小板减少性紫癜,改用他克莫司并进行血浆置换后病情缓解。另1例血液计数正常的患者在移植后第241天死于感染。移植后6个月的嵌合体研究证实,所有7例接受检测的患者造血均来源于供体。无一例患者发生急性或慢性移植物抗宿主病(GvHD)。无迟发性移植物失败,94%的患者在移植后中位1303.5天(范围216 - 2615天)无病存活。
在这组多次输血的患者中,本研究中描述的含放疗方案尽管去除了T细胞,但仍能实现普遍造血重建且毒性有限。无一例患者发生GvHD或晚期移植物失败。应进一步探索更低剂量的含放疗预处理方案。